...
首页> 外文期刊>Pharmaceutical Biology >Inhibition of invasion and metastasis of human liver cancer HCCLM3 cells by portulacerebroside A
【24h】

Inhibition of invasion and metastasis of human liver cancer HCCLM3 cells by portulacerebroside A

机译:马齿re脑苷脂A抑制人肝癌HCCLM3细胞的侵袭和转移

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Context: Portulacerebroside A (PCA) is a novel cerebroside compound isolated from Portulaca oleracea L. (Portulacaceae), an edible and medicinal plant distributed in the temperate and tropical zones worldwide.Objective: This study investigates the effects of PCA in human liver cancer HCCLM3 cells on metastasis and invasion.Materials and methods: After the cells were treated with PCA (2.5, 5, and 10?μg/ml) for 6, 12, 24, or 48?h, adhesion, transwell invasion, and scratch tests were conducted and cell functions were evaluated. Western blot and FQ-RT-PCR assays explored the mechanism of PCA-inhibited invasion and metastasis in the cells.Results: The adhesion rate of the cells was suppressed at 0.5?h (79.4?±?1.0, 68.7?±?1.3, and 58.1?±?1.3%, versus 100?±?1.5% in the control), 1?h (78.2?±?1.2, 70.9?±?1.6, and 55.4?±?1.9%, versus 100?±?1.2% in the control), and 1.5?h (71.6?±?1.1, 62.3?±?0.9, and 50.4?±?0.9%, versus 100?±?1.1% in the control). The 24?h invasion ability was decreased (356.6?±?11.2, 204.0?±?17.6, and 113.0?±?9.5%, versus 443.6?±?15.4% in the control). The migration capability was also restrained by PCA for 24?h (324.8?±?25.4, 250.4?±?21.0, and 126.3?±?10.1, versus 381.6?±?30.6 in the control) and 48?h (470.3?±?34.3, 404.0?±?19.7, and 201.0?±?15.4, versus 752.0?±?63.6 in the control). There was an increase in the mRNA and protein expression levels of TIMP-2 and nm23-H1, inhibition in the mRNA expression of MTA1, MMP-2, and MMP-9, and suppression in the protein expression of MTA1, RhoA, Rac1/Cdc42, MMP-2, but not RhoC and MMP-9.Conclusion: PCA suppresses the invasion and metastasis of HCCLM3 cells possibly by modulation of the mRNA and protein expression of related parameters. This is the first study to reveal a new potential therapeutic application of PCA in antimetastatic therapy for liver cancer.
机译:背景:马齿re脑苷B(PCA)是一种新的脑苷脂化合物,从世界各地的温带和热带分布的食用和药用植物马齿Port(Portulaca oleracea L.)中分离而来。目的:本研究旨在研究PCA对人肝癌HCCLM3的影响。材料和方法:将细胞分别用PCA(2.5、5和10?μg/ ml)处理6、12、24或48?h后,进行粘附,穿透孔侵袭和刮擦试验。进行细胞功能评估。 Western blot和FQ-RT-PCR检测了PCA抑制细胞侵袭和转移的机制。结果:细胞的粘附率被抑制为0.5?h(79.4?±?1.0、68.7?±?1.3,和58.1%±1.3%,而对照组为100%±1.5%),1小时(78.2%±1.2、70.9%±1.6和55.4%±1.9%,而100%±1.2% %和1.5μh(对照中为71.6±1.0,62.3±0.9和50.4±0.9%,而对照为100±1.1%)。 24小时的侵袭能力降低(356.6±11.2、204.0±17.6和113.0±9.5%,而对照组为443.6±15.4%)。 PCA也将迁移能力抑制了24?h(324.8?±?25.4、250.4?±?21.0和126.3?±?10.1,而对照组为381.6?±?30.6)和48?h(470.3?± 34.3、404.0±19.7和201.0±15.4,而对照组为752.0±63.6。 TIMP-2和nm23-H1的mRNA和蛋白表达水平增加,MTA1,MMP-2和MMP-9的mRNA表达受到抑制,MTA1,RhoA,Rac1 /的蛋白表达受到抑制。 Cdc42,MMP-2,但不是RhoC和MMP-9。结论:PCA可能通过调节相关参数的mRNA和蛋白表达来抑制HCCLM3细胞的侵袭和转移。这是第一项揭示PCA在肝癌抗转移疗法中新的潜在治疗应用的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号